Participant flow

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer · Source last updated 2022-07-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

   id

   FG000

   title

   Nivolumab Arm

2. description

   Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends OR Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

   id

   FG001

   title

   Active Comparator Arm （Docetaxel/Paclitaxel）

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. comment

         Included in intention-to-treat analysis for overall survival and progression-free survival

         group Id

         FG000

         num Subjects

         210

      2. comment

         Included in intention-to-treat analysis for overall survival and progression-free survival

         group Id

         FG001

         num Subjects

         209

      comment

      Enrolled and randomly assigned

      type

      STARTED

   2. achievements

      1. comment

         Analysed for safety

         group Id

         FG000

         num Subjects

         209

      2. comment

         Analysed for safety

         group Id

         FG001

         num Subjects

         208

      comment

      Received assigned treatment of IMP

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice